We lower BYRCS's topline, EBITDA & APAT estimates by 2%/3%/3% for FY21E, 3%/7%/6% for FY22E & 4%/5%/5% for FY23E to factor in lower topline growth and reduced gross margin expansion than earlier anticipated. We downgrade the stock to ACCUMULATE (from BUY) with revised TP of Rs 6090 (Previous 6421) based on 35x Sept'22 EPS of Rs 167. We continue to like the stock due to its lean business model, robust cash flow generation and superior return ratios of ~20-25%. BYRCS's 3% topline growth was largely...